Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Hematology
In a patient newly diagnosed with mantle cell lymphoma who has focal intracerebral disease and has received SRS, what is the benefit to adding a BTK-inhibitor such as ibrutininb to chemotherapy?
Related Questions
How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
What is the preferred treatment for a patient with an EBV+ monomorphic PTLD (DLBCL) not currently on immunosuppressive therapy?
How are you deciding between available third line therapies for post-transplant relapsed DLBCL?
What are the most important factors that you use to decide between R-CHOP vs R-miniCHOP in elderly or frail patients with DLBCL?
What subsequent therapies did patients receive after progressing on pirtobrutinib in the mantle cell BRUIN trial population?
How do you manage grade 1-3A Follicle Center Lymphoma of the lower female genital tract, presenting with a cervical mass?
When would you consider treating an asymptomatic patient with follicular lymphoma?
How would you manage a patient with p53 mutated MCL who has progressed after a BTKi and CAR-T with a CD20 negative clone?
What factors do you consider when sequencing bispecific T-cell engaging antibodies and CAR T-cell therapies for the treatment of follicular lymphoma?
What is your preferred second line regimen for follicular lymphoma that has relapsed four years out since receiving BR?
